Lisa M. Sharkey

Lisa M. Sharkey

Auto-generated profile, based on publicly available information

Lisa M. Sharkey

Department of Neurology, University of Michigan, Ann Arbor, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2020 in Neurobiology of Disease
Verified
Journal Article
Open access
LSLisa M. Sharkey
Lisa M. Sharkey
SSStephanie S. Sandoval-Pistorius
Stephanie S. Sandoval-Pistorius
SMShannon J. Moore
Shannon J. Moore
JGJulia E. Gerson
Julia E. Gerson
RKRobert Komlo
Robert Komlo
HPHenry L. Paulson
Henry L. Paulson
The ubiquitin-binding proteasomal shuttle protein UBQLN2 is implicated in common neurodegenerative disorders due to its accumulation in disease-specific aggregates and, when mutated, directly causes familial frontotemporal dementia/amyotrophic lateral sclerosis (FTD/ALS). Like other proteins linked to FTD/ALS, UBQLN2 undergoes phase separation to form condensates. The relationship of UBQLN2 phase separation and accumulation to neurodegeneration, however, remains uncertain. Employing biochemical, neuropathological and behavioral assays, we studied the impact of overexpressing WT or mutant UBQLN2 in the CNS of transgenic mice. Expression of UBQLN2 harboring a pathogenic mutation (P506T) elicited profound and widespread intraneuronal inclusion formation and aggregation without prominent neurodegenerative or behavioral changes. Both WT and mutant UBQLN2 formed ubiquitin- and P62-positive inclusions in neurons, supporting the view that UBQLN2 is intrinsically prone to phase separate, with the size, shape and frequency of inclusions depending on expression level and the presence or absence of a pathogenic mutation. Overexpression of WT or mutant UBQLN2 resulted in a dose-dependent decrease in levels of a key interacting chaperone, HSP70, as well as dose-dependent profound degeneration of the retina. We conclude that, at least in mice, robust aggregation of a pathogenic form of UBQLN2 is insufficient to cause neuronal loss recapitulating that of human FTD/ALS. Our results nevertheless support the view that altering the normal cellular balance of UBQLN2, whether wild type or mutant protein, has deleterious effects on cells of the CNS and retina that likely reflect perturbations in ubiquitin-dependent protein homeostasis.

1 November 2007 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
LSLisa M. Sharkey
Lisa M. Sharkey
SMSamuel G. Madamba
Samuel G. Madamba
GSGeorge R. Siggins
George R. Siggins
TBTamas Bartfai
Tamas Bartfai

5 March 2022 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
HMHarihar Milaganur Mohan
Harihar Milaganur Mohan
HTHanna Trzeciakiewicz
Hanna Trzeciakiewicz
APAmit Pithadia
Amit Pithadia
ECEmily V. Crowley
Emily V. Crowley
RPRegina Pacitto
Regina Pacitto
LSLisa M. Sharkey
Lisa M. Sharkey

13 March 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NSNathaniel Safren
Nathaniel Safren
TDThuy P. Dao
Thuy P. Dao
HMHarihar Milaganur Mohan
Harihar Milaganur Mohan
CHCamellia Huang
Camellia Huang
BTBryce Trotter
Bryce Trotter
LSLisa M. Sharkey
Lisa M. Sharkey
The ubiquitin-adaptor protein UBQLN2 promotes degradation of several aggregate-prone proteins implicated in neurodegenerative diseases. Missense UBQLN2 mutations also cause X-linked amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Previously we demonstrated that the liquid-like properties of UBQLN2 molecular assemblies are altered by a specific pathogenic mutation, P506T, and that the propensity of UBQLN2 to aggregate correlated with neurotoxicity. Here, we systematically assess the effects of multiple, spatially distinct ALS/FTD-linked missense mutations on UBQLN2 aggregation propensity, neurotoxicity, phase separation, and autophagic flux. In contrast to what we observed for the P506T mutation, no other tested pathogenic mutant exhibited a clear correlation between aggregation propensity and neurotoxicity. These results emphasize the unique nature of pathogenic UBQLN2 mutations and argue against a generalizable link between aggregation propensity and neurodegeneration in UBQLN2-linked ALS/FTD.

29 August 2020 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
JGJulia E Gerson
Julia E Gerson
NSNathaniel Safren
Nathaniel Safren
SFSvetlana Fischer
Svetlana Fischer
RPRonak Patel
Ronak Patel
ECEmily V Crowley
Emily V Crowley
LSLisa M Sharkey
Lisa M Sharkey
Divergent protein context helps explain why polyglutamine expansion diseases differ clinically and pathologically. This heterogeneity may also extend to how polyglutamine disease proteins are handled by cellular pathways of proteostasis. Studies suggest, for example, that the ubiquitin-proteasome shuttle protein Ubiquilin-2 (UBQLN2) selectively interacts with specific polyglutamine disease proteins. Here we employ cellular models, primary neurons and mouse models to investigate the potential differential regulation by UBQLN2 of two polyglutamine disease proteins, huntingtin (HTT) and ataxin-3 (ATXN3). In cells, overexpressed UBQLN2 selectively lowered levels of full-length pathogenic HTT but not of HTT exon 1 fragment or full-length ATXN3. Consistent with these results, UBQLN2 specifically reduced accumulation of aggregated mutant HTT but not mutant ATXN3 in mouse models of Huntington’s disease (HD) and spinocerebellar ataxia type 3 (SCA3), respectively. Normally a cytoplasmic protein, UBQLN2 translocated to the nuclei of neurons in HD mice but not in SCA3 mice. Remarkably, instead of reducing the accumulation of nuclear mutant ATXN3, UBQLN2 induced an accumulation of cytoplasmic ATXN3 aggregates in neurons of SCA3 mice. Together these results reveal a selective action of UBQLN2 toward polyglutamine disease proteins, indicating that polyglutamine expansion alone is insufficient to promote UBQLN2-mediated clearance of this class of disease proteins. Additional factors, including nuclear translocation of UBQLN2, may facilitate its action to clear intranuclear, aggregated disease proteins like HTT.

1 May 2009 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
LSLisa M. Sharkey
Lisa M. Sharkey
JJJulie M. Jones
Julie M. Jones
Peter HederaPeter Hedera
Peter Hedera
MMMiriam H. Meisler
Miriam H. Meisler